ClearPoint Neuro prelim Q4 revenue rises

Clearpoint Neuro

12/01/2026 13:40

Overview

Device and therapy firm's preliminary Q4 revenue rose 20% yr/yr to $10.4 mln

Company expects 2026 revenue between $54 mln and $60 mln

Preliminary results show growth in neurosurgery disposables and biologics delivery

Outlook

ClearPoint Neuro expects 2026 revenue between $54 mln and $60 mln

Company anticipates double-digit growth in all four existing markets in 2026

ClearPoint Neuro plans commercial launch of neuro cell and gene therapies in future

Result Drivers

NEUROSURGERY AND BIOLOGICS GROWTH - Functional neurosurgery disposables and biologics and drug delivery saw growth rates of 23% and 26% respectively, according to CEO Joe Burnett

IRRAFLOW CONTRIBUTION - Revenue growth partially included sales from the newly acquired IRRAflow product line

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$10.40 mln
$10.30 mln (2 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Clearpoint Neuro Inc is $29.00, about 94.4% above its January 9 closing price of $14.92

Press Release: ID:nACSSSgFDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)